Outlook Therapeutics, Inc.
Moderate confidence (50%)
Updated Oct 17, 2026, 12:04 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Outlook Therapeutics, Inc. received a delisting notice from its exchange (Sep 25, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Outlook Therapeutics, Inc. received a delisting notice from its exchange
Sep 25, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On September 25, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the Company ), received a letter from the Listing Qualifications Staff (the Nasdaq Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that for the last 30 consecutive business days, the bid price of the Company s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification re…”
Outlook Therapeutics, Inc. received a delisting notice from its exchange
Jun 26, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . As previously reported, on February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the Company ), received a letter from the Listing Qualifications Staff (the Nasdaq Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that Nasdaq staff had determined to delist the Company s common stock, par value $0.01 per share (the Common Stock ) from the Nasdaq Capital Market because it failed to maintain a minimum bid price of $1.00 per share for 30 consecutiv…”
Outlook Therapeutics, Inc. received a delisting notice from its exchange
Feb 18, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the Company ), received a letter from the Listing Qualifications Staff (the Nasdaq Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that for the last 30 consecutive business days, the bid price of the Company s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification rec…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Biological Products, (No Diagnostic Substances)
- Subindustry
- —
- Listing
- SEC lists the ticker OTLK on Nasdaq.
- SEC CIK
- 0001649989
- Website
- —
- —
- Headquarters
- ISELIN
- Also known as
- Oncobiologics, Inc.
- Legal entities
- Outlook Therapeutics, Inc.
Sources
Every material source used to build this profile.
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On September 25, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the Company ), received a letter from the Listing Qualifications Staff (the Nasdaq Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that for the last 30 consecutive business days, the bid price of the Company s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification re…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the Company ), received a letter from the Listing Qualifications Staff (the Nasdaq Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that for the last 30 consecutive business days, the bid price of the Company s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification rec…
View source recordSEC Company Submissions (TIER 1 · UNVERIFIED)
Outlook Therapeutics, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — ISELIN, NJ
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . As previously reported, on February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the Company ), received a letter from the Listing Qualifications Staff (the Nasdaq Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that Nasdaq staff had determined to delist the Company s common stock, par value $0.01 per share (the Common Stock ) from the Nasdaq Capital Market because it failed to maintain a minimum bid price of $1.00 per share for 30 consecutiv…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:29 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:13 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:16 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.